Treatment of lipodystrophy
AssigneeArk Therapeutics, Ltd.
InventorsJohn Francis Martin, Jorge D. Erusalimsky, Hugh Edward Montgomery
Life of this patent
Estimating the term…
Abstract
An inhibitor of the renin-angiotensin system is useful for the treatment or prevention of the lipodystrophy syndrome, e.g. in AIDS patients also receiving anti-retroviral therapy.
Claims6
A method for the treatment of lipodystrophy syndrome wherein said method comprises administering, to a patient in need of such treatment, an effective amount of an inhibitor of the renin-angiotensin system, wherein the inhibitor of the renin-angiotensin system is selected from the group consisting of quinapril, captopril, lisinopril, perindopril, trandolapril, enalapril, moexipril, fosinopril, ramipril, cilazapril, imidapril, spirapril, temocapril, benazepril, alacepril, ceronapril, cilazapril, delapril, enalaprilat, moveltipril, losartan, valsartan, irbesartan, candesartan, eprosartan, tasosartan, and telmisartan;
- and wherein the lipodystrophy syndrome is in a patient undergoing anti-retroviral therapy.
Dependencies are inferred from the claim text.